| General Information | |
|---|---|
| ZINC ID | ZINC000040425145 |
| Molecular Weight (Da) | 448 |
| SMILES | CCCc1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)o1 |
| Molecular Formula | C21Cl3N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 118.267 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| LogP | 7.124 |
| Activity (Ki) in nM | 158.489 |
| Polar Surface Area (PSA) | 56.74 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.90553313 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.19 |
| Ilogp | 4.29 |
| Xlogp3 | 6.52 |
| Wlogp | 6.81 |
| Mlogp | 5.17 |
| Silicos-it log p | 6.49 |
| Consensus log p | 5.86 |
| Esol log s | -6.95 |
| Esol solubility (mg/ml) | 0.0000497 |
| Esol solubility (mol/l) | 0.00000011 |
| Esol class | Poorly sol |
| Ali log s | -7.51 |
| Ali solubility (mg/ml) | 0.0000139 |
| Ali solubility (mol/l) | 0.00000003 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.74 |
| Silicos-it solubility (mg/ml) | 8.17E-08 |
| Silicos-it solubility (mol/l) | 1.82E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.4 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.54 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.938 |
| Logd | 5.197 |
| Logp | 6.109 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 98.29% |
| Vdss | 3.395 |
| Fu | 2.25% |
| Cyp1a2-inh | 0.383 |
| Cyp1a2-sub | 0.554 |
| Cyp2c19-inh | 0.905 |
| Cyp2c19-sub | 0.119 |
| Cl | 3.86 |
| T12 | 0.035 |
| H-ht | 0.179 |
| Dili | 0.974 |
| Roa | 0.561 |
| Fdamdd | 0.236 |
| Skinsen | 0.041 |
| Ec | 0.003 |
| Ei | 0.015 |
| Respiratory | 0.71 |
| Bcf | 3.57 |
| Igc50 | 5.114 |
| Lc50 | 6.228 |
| Lc50dm | 5.633 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.133 |
| Nr-ahr | 0.237 |
| Nr-aromatase | 0.932 |
| Nr-er | 0.914 |
| Nr-er-lbd | 0.388 |
| Nr-ppar-gamma | 0.159 |
| Sr-are | 0.96 |
| Sr-atad5 | 0.319 |
| Sr-hse | 0.124 |
| Sr-mmp | 0.905 |
| Sr-p53 | 0.899 |
| Vol | 409.592 |
| Dense | 1.089 |
| Flex | 0.227 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.337 |
| Synth | 2.456 |
| Fsp3 | 0.19 |
| Mce-18 | 23 |
| Natural product-likeness | -1.625 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |